Journal of Mid-life Health Journal of Mid-life Health
Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission | Subscribe | Advertise Users Online: 1010  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 




 
 Table of Contents 
COMMENTARY
Year : 2019  |  Volume : 10  |  Issue : 1  |  Page : 43-44  

Editor's Comment on – “A Clinical Study of a Standardized Extract of Leaves of Dalbergia sissoo (Roxb ex DC) in Postmenopausal Osteoporosis”


Director, Division of Gynaecologic Oncology, Prayaas Clinic, Jaipur, Rajasthan, India

Date of Web Publication29-Mar-2019

Correspondence Address:
Ranu Patni
14, Pradhan Marg, Malviya Nagar, Jaipur - 302 017, Rajasthan
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0976-7800.255283

Rights and Permissions

How to cite this article:
Patni R. Editor's Comment on – “A Clinical Study of a Standardized Extract of Leaves of Dalbergia sissoo (Roxb ex DC) in Postmenopausal Osteoporosis”. J Mid-life Health 2019;10:43-4

How to cite this URL:
Patni R. Editor's Comment on – “A Clinical Study of a Standardized Extract of Leaves of Dalbergia sissoo (Roxb ex DC) in Postmenopausal Osteoporosis”. J Mid-life Health [serial online] 2019 [cited 2019 Jul 18];10:43-4. Available from: http://www.jmidlifehealth.org/text.asp?2019/10/1/43/255283



Postmenopausal osteoporosis (PMO) is a serious public health concern due to its silent nature, its first presentation as a fracture in majority of cases, significant morbidity and mortality caused by fractures and their complications, compromised quality of life and heavy economic burden on the individual, the society and the country. The use of currently available anti-osteoporotic agents is restricted many a times by their side effects. HT has fallen out of favor to a significant extent after the publication of the Women's Health Initiative Study results. Following the ever-evolving need of the society and by virtue of its inherent nature, research continues to look for ideal agents for the management of all medical conditions with an aim to improve efficacy and reduce adverse effects. So is the case with PMO.

This is a small but well-conducted open-label study. The outcomes have been encouraging in the form of anti-osteoporotic and anti-inflammatory properties of the Standardized Extract of Leaves of Dalbergia sissoo for PMO with a favorable safety profile in fixed doses. The potential anti-arthritic property of the drug is evident not only by a fall in the marker but also by a significant improvement in musculoskeletal symptoms. However, the dropout rate was higher than an acceptable <10%. Like the authors have also mentioned, a flexible dose schedule needs to be studied while ascertaining the effect of the drug on bone-specific markers. The newer drug needs to be studied in depth in terms of interactions with other agents, cost effectiveness, etc.

This should form the basis of larger randomized controlled trials to further study this seemingly promising new drug.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.






 

Top
  
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article

 Article Access Statistics
    Viewed156    
    Printed14    
    Emailed0    
    PDF Downloaded31    
    Comments [Add]    

Recommend this journal